Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroids
Cassiopea S.p.A.
Test of vasocontriction properties for classification of topical steroid potency
1 trial -
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
Orion Laboratories Pty.
short-term treatment of insomnia
1 trial -
CITY
Pari Pharma GmbH
Cutaneous T-cell lymphomas (CTCL)
1 trial -
Comparison between ABP 234 and Keytruda® (Pembrolizumab)
Amgen
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
Comparison of Prefilled syringe and Autoinjector presentations of FYB202
Fresenius Kabi Australia Pty Limited
Chronic inflammatory diseases
1 trial -
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.
Chiesi Farmaceutici S.p.A
Asthma and chronic obstructive pulmonary disease (COPD).
1 trial -
Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)
Pari Pharma GmbH
Oncology: RELAPSED PRIMARY CNS LYMPHOMA
1 trial -
HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies
Pari Pharma GmbH
hematologic malignancies ; acute myeloid leukemias
1 trial -
In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)
Pari Pharma GmbH
Cardiology and vascular disease
1 trial -
MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension
Pari Pharma GmbH
Familial Hemophagocytic Lymphohistiocytosis (FHL)
1 trial -
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Niraparib
Takeda
Advanced Solid Tumors
1 trial -
Olaparib tablets, 150 mg
Sandoz Pty Ltd
Ovarian Cancer
1 trial -
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.
Bioprojet Pharma
narcolepsy with cataplexy, Narcolepsy
1 trial -
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects
Bioprojet Pharma
Narcolepsy, Narcolepsy with cataplexy
1 trial -
Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.
Lacuna Pharma Pty Ltd
not applicable (submitted trial is a bioequivalence study)
1 trial -
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
Swedish Orphan Biovitrum AB (publ)
Haemophilia A
1 trial -
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
Lacuna Pharma Pty Ltd
Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis
1 trial -
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.
Lacuna Pharma Pty Ltd
Comparative bioavailability study under fasting conditions
1 trial -
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.
Lacuna Pharma Pty Ltd
not applicable (submitted trial is a bioequivalence in healthy subjects)
1 trial -
Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S.A.) to Trajenta® 5 mg film-coated tablets (Boehringer Ingelheim) in healthy volunteers under fasting conditions.
Alphapharm Pty Ltd
Bioequivalence study in healthy volunteers under fasting conditions
1 trial -
SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells
Pari Pharma GmbH
Non-ischemic Dilated Cardiomyopathies
1 trial -
Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.
Pari Pharma GmbH
Comparative bioequivalence study in healthy volunteers under fasting conditions.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources